U.S. Markets open in 2 hrs 7 mins

PharmAthene, Inc. (PIP)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.6500-0.05 (-7.75%)
At close: 4:00PM EDT
People also watch
  • Guys Chemotherapy meaning FDA aleady approval.

    Chemotherapy ALready in sale


    Manufacturing certificates are available by clicking on the icon.
    Click Reimbursement Information to view displayed items with the Reimbursement Information.

    Order Code

    Medical Labels
  • With the Reverse Merger and added pipeline the stock is worth about $3.00 a share pre Reverse Split price, so in my estimation $30.00 a share is fair value. Time will prove that this is correct.
  • Reverse split 1/10. Pip alone (before merger) worth $6.50 pps. Now merged with altimmune today, its worth less than $6.50. Sorry Mr. Shorty dont buy it.
  • I just want to thank the management of PIP. Really a big THANK YOU. Not only did they share the lions share of the SIGA settlement monies with their shareholders, and instead of closing their doors, continue to gain shareholder value with the merger of Altimmune. Not many if any companies out there that give two schits about there shareholders. I've been holding since 2010, not expecting this lawsuit to go on this long, but 7 years is a long time. I'm glad I hung on, its been worth it. Again, Thank You PIP MANAGEMENT.
  • Join the Party

    ALT Conversations | Altimmune, Inc. - Yahoo Finance
    Welcome to largest financial internet forum where people can hold conversations related to stock trading and investing in equities. You can share your opinion and views on various topics from exciting world of finance.
  • Now that the merger and split have occurred, why hasn't Yahoo also moved this Conversation board over to ALT? As of now ALT has no blog or Conversation board at all and this one should, IMHO, be defunct or moved over. Anyone have a method to do so?

    By the way, despite my YAHOO login and persona, when I post here it gives me a generic name of Yahoo Reader, which is not correct. does anyone know how to post the correct one or to get their attention. It shows it correctly on my Browser page for Yahoo Finance, but not for these posts. Just asking
  • Someone can explain to me I do not understand anything I had 87000 in pip I bought them at 1.25 I had a value of 108750.00 I had a loss of 38280.00 I found that I had 8700 shares but valued at 6.15 which is an average of 53515.00 where the rest of my money is
  • Although i sold my shares at .71 at a loss,i still will keep my eye on ALT since low price reverse split stocks have been the most manipulated in the market and if those groups gab hold of it don't be too greedy?
  • Do we know the R/S ratio already? The company would have to announce an outcome of the meeting between now and tomorrow BMO.

    Thank you PIP for a great ride, and long live ALT!
  • I figure that the stock price Doubles to $14 during May and Triples to $21 during June.
  • can someone let me know why this stock is temporarily untradeable ?
  • a nice green finish without all brokerages allowing trade yet. should be a great week let see $10+
  • Reverse splits almost always suck.
  • Good morning and what is going to happen now with the shares that had been bought canvian to this new company atl one to one or 10 by one
  • Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
    Thursday, May 4, 2017 8:04 PM UTC 0 comments
    GAITHERSBURG, Md., May 04, 2017 -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage drug-development programs.

    Bill Enright, President and Chief Executive Officer of Altimmune, and Elizabeth Czerepak, Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, will serve in their respective positions in the combined company. The new board of directors will be initially comprised of three PharmAthene directors and four Altimmune directors. The combined company’s headquarters is located in Gaithersburg, MD.

    Additionally, the company announced that immediately prior to the merger, it effectuated a 1-for-10 reverse stock split of outstanding shares of its common stock. As a result of the reverse stock split, each 10 shares of common stock outstanding immediately prior to the merger were converted into one share of common stock.

    Mr. Enright stated: “We congratulate and thank the employees and shareholders of both companies for their approval of this merger, which will bring together complementary vaccine development programs and allow us to leverage our substantial financial and human resources effectively in support of these programs.”

    Altimmune will focus its drug-development activities on the following proprietary vaccine candidates:

    NasoVAX: an intranasal, single dose, state-of-the-art recombinant influenza vaccine that in preclinical studies demonstrated early and universal activity. Phase 2 is expected to commence during 3Q2017 with initial data expected in 1Q18.
    HepTcell: a first-in-class immunotherapeutic for chronic hepatitis B with the potential to offer a functional cure. Phase 1 is ongoing with initial data expected 4Q17.
    SparVax-L: a next generation lyophilized anthrax vaccine (NIAID funded) that may be stored at room temperature and provides extended shelf life. A non-human primate bridging study is anticipated to begin during the second half of 2017 with data anticipated during the first half of 2018.
    NasoShield: an intranasal, single-dose, first-in-class anthrax vaccine (BARDA funded) that based on preclinical studies may offer protection within a few weeks of administration. A Phase 1 trial is expected to begin during 1Q18 with data anticipated 2Q18.
    In addition to the clinical-stage product candidates, Altimmune has one preclinical program, Oncosyn, driven by its proprietary Densigen synthetic peptide technology that is being evaluated in immuno-oncology indications.
  • Merely speculating the value of PIP shares once converted to ALT, PIP=$1.935
  • I disagree with any negativity and look at this situation and think that the stock is a 5X, 6X or 7X, after the price action settles down and analysts can determine a fair value for the newly merged company and encouraging news is issued.

    The circumstances surrounding this Reverse Split are unprecedented:
    1. A possible record setting percentage to stock price ex-dividend cash payout with PIP to stockholders resulting from a lawsuit.
    2. A Reverse Merger with a private company and a great pipeline, coming onto market as ALT.
    3. A Reverse Split.

    100,000 PIP shares
    10,000 ALT shares
  • Congrats on the incredible management team, doing the right thing for once!
  • The stupidity of shareholders giving their shares to bashers is beyond my comprehension. 2 mil loss with a bio is tiny loss compared to the bio threat facing America and the vacines needed. all in pip's bag of toys. BUY BUY BUY
  • ?!?!?!?!?!?!?!?!?!?!?!?
    $7.91, +1.41 & +21.69%

    Today is Cinco de Mayo, as if I needed an excuse. But after that wild ride today, commenced with the trade at the close that catapulted the stock price, I just poured myself a second shot of Tequila.